AstraZeneca

News

ADRIATIC buoys Imfinzi’s prospects in early lung cancer

After a setback in a trial of Imfinzi in early non-small cell lung cancer (NSCLC) last year, AstraZeneca has clawed back some ground with a positive result in small-cell l

News

AZ, Daiichi Sankyo file Dato-DXd for second indication

AstraZeneca and Daiichi Sankyo have moved swiftly to file for FDA approval of a second indication for their TROP2-directed antibody-drug conjugate datopotamab deruxtecan (

News

FDA clears AZ’s new PNH therapy Voydeya

AstraZeneca’s Voydeya has become the first oral Factor D inhibitor to be approved by the FDA as a treatment for the rare disease paroxysmal nocturnal haemoglobinuria (PNH)

Patients

Case Study: MHRA and AstraZeneca

Agile, responsive regulation helps early breast cancer patients to benefit from a study to potentially improve survival outcomes.

News

Brainomix AI shows its worth in AZ pulmonary fibrosis trial

Artificial intelligence-powered software developed by Brainomix has been shown to identify patients with idiopathic pulmonary fibrosis (IPF) at risk of decline in a clinic

News

At second ask, FDA clears AZ’s Ultomiris for NMOSD

AstraZeneca’s Ultomiris has been approved by the FDA to treat rare autoimmune disease neuromyelitis optica spectrum disorder (NMOSD), six months after an earlier applicati

ADRIATIC buoys Imfinzi’s prospects in early lung cancer

AZ, Daiichi Sankyo file Dato-DXd for second indication

FDA clears AZ’s new PNH therapy Voydeya

Case Study: MHRA and AstraZeneca

Brainomix AI shows its worth in AZ pulmonary fibrosis trial

At second ask, FDA clears AZ’s Ultomiris for NMOSD

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

AstraZeneca

Editor's Picks